Open |
EAY191-S3 |
ComboMATCH S3 |
3/6/2023 |
|
3% |
|
|
Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
Open |
S1501 |
Carvedilol vs No Trt in Prevention of Cardiac Dysfunction in HER-2+ mBrCa |
9/15/2017 |
|
38% |
|
|
Open |
S1608 |
Randomized Ph II for Relapsed Refractory FL |
8/10/2017 |
|
81% |
|
|
Open |
S1609 |
DART |
1/13/2017 |
|
98% |
|
|
Open |
S1703 |
Disease Monitoring Study |
7/16/2018 |
|
45% |
|
|
Open |
S1706 |
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast |
9/12/2018 |
|
51% |
|
|
Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
62% |
|
|
Open |
S1803 |
PIII Daratumumab + Lenalidomide Post-Auto SCT Maint for MM |
6/27/2019 |
|
100% |
|
|
Open |
S1823 |
miRNA 371 Study in Germ Cell Tumors |
6/1/2020 |
|
99% |
|
|
Open |
S1827 |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) |
1/10/2020 |
|
32% |
|
|
Open |
S1900E |
LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study |
4/2/2021 |
|
97% |
|
|
Open |
S1900G |
Comparing Combinations of Targeted Drugs for Advanced NSCLC that has EGFR and MET Gene Changes |
4/3/2023 |
|
17% |
|
|
Open |
S1900K |
Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change |
12/18/2023 |
|
0% |
|
|
Open |
S1904 |
Decision Support Tool |
9/1/2020 |
|
96% |
|
|
Open |
S1905 |
PI/II OBI-3424 for R/R T-ALL/T-LBL |
8/17/2020 |
|
22% |
|
|
Open |
S1912CD |
CREDIT |
7/26/2021 |
|
72% |
|
|
Open |
S1914 |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC |
3/25/2020 |
|
74% |
|
|
Open |
S1918 |
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL |
3/19/2021 |
|
23% |
|
|
Open |
S1922 |
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma |
12/16/2019 |
|
34% |
|
|